http://hl7.org/fhir/uv/ebm/Composition/236951
type: Composition
node role: treeRoot
id:
  v: 236951
meta:
  version id:
    v: 107
  last updated:
    v: 2025-10-07T17:12:54.639Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/summary-of-findings
    l: summary-of-findings
language:
  v: en
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Composition 236951 version: 107; Last updated: 2025-10-07 17:12:54+0000; Language: en Profile: SummaryOfFindings url: https://fevir.net/resources/Composition/236951 identifier: FEvIR Object Identifier/236951, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-summary-of-findings-85394-85798 status: Final type: Summary of Findings date: 2025-10-07 17:12:54+0000 author: Qiukui Hao title: SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes custodian: Computable Publishing LLC relatesTo type: Part Of target: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report) relatesTo type: Part Of target: ComparativeEvidenceSynthesisReport: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-comparative-evidence-report-85394-85798) relatesTo type: Cite As target: SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236951. Revised 2025-10-07. Available at: https://fevir.net/resources/Composition/236951. Computable resource at: https://fevir.net/resources/Composition/236951#json.
url:
  v: https://fevir.net/resources/Composition/236951
  l: https://fevir.net/resources/Composition/236951
identifier:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v2-0203
        l: v2-0203
      code:
        v: ACSN
      display:
        v: Accession ID
    text:
      v: FEvIR Object Identifier
  system:
    v: https://fevir.net/FOI
    l: FOI
  value:
    v: 236951
  assigner:
    display:
      v: Computable Publishing LLC
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: MAGIC-5288-j1Wqrn-summary-of-findings-85394-85798
  assigner:
    display:
      v: Computable Publishing LLC
status:
  v: final
type:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: SummaryOfFindings
    display:
      v: SummaryOfFindings
  text:
    v: Summary of Findings
date:
  v: 2025-10-07T17:12:54.639Z
author:
  display:
    v: Qiukui Hao
title:
  v: SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
custodian:
  l: http://hl7.org/fhir/uv/ebm/Organization/118079
  reference:
    v: Organization/118079
  type:
    v: Organization
    l: Organization
  display:
    v: Computable Publishing LLC
relates to:
  type:
    v: part-of
  target: Reference
    type:
      v: Composition
      l: Composition
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-conversion-report
    display:
      v: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes
relates to:
  type:
    v: part-of
  target: Reference
    type:
      v: Composition
      l: Composition
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-comparative-evidence-report-85394-85798
    display:
      v: ComparativeEvidenceSynthesisReport: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
relates to:
  type:
    v: cite-as
  target: Markdown
    v: SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236951. Revised 2025-10-07. Available at: https://fevir.net/resources/Composition/236951. Computable resource at: https://fevir.net/resources/Composition/236951#json.
section:
  title:
    v: Column Headers
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: column-headers
      display:
        v: Column Headers
  section:
    title:
      v: Outcome Measure
    text:
      status:
        v: generated
      div:
        v: Outcome
  section:
    title:
      v: Sample Size
    text:
      status:
        v: generated
      div:
        v: Sample Size
  section:
    title:
      v: Result Without Treatment
    text:
      status:
        v: generated
      div:
        v: Result Without Treatment
  section:
    title:
      v: Result With Treatment--Observed
    text:
      status:
        v: generated
      div:
        v: Result With Treatment (Observed)
  section:
    title:
      v: Result With Treatment--Derived
    code:
      text:
        v: result with intervention with calculated value derived from the control group and effect estimate
    text:
      status:
        v: generated
      div:
        v: Result With Treatment (Calculated)
  section:
    title:
      v: Effect Estimate
    text:
      status:
        v: generated
      div:
        v: Effect Estimate
  section:
    title:
      v: Certainty of Evidence
    text:
      status:
        v: generated
      div:
        v: Certainty of Evidence
  section:
    title:
      v: Assertion
    text:
      status:
        v: generated
      div:
        v: What this means
section:
  title:
    v: Summary of Findings
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: outcome-measure

v: Outcome Measure

v: sample-size

v: Sample Size

v: result-with-comparator-alone

v: Result with comparator alone

v: result-with-intervention-alone

v: Result with intervention alone

v: result-with-intervention-alone-calculated

v: Result with intervention alone (calculated)

v: result-with-intervention-vs-comparator

v: Result with intervention vs. comparator

v: certainty-of-evidence

v: Certainty of Evidence

v: assertion

v: Assertion

v: summary-of-findings

v: Summary of Findings

status:
  v: empty
div:
  v: [No data.]

coding:
  system:
    v: http://terminology.hl7.org/CodeSystem/list-empty-reason
    l: list-empty-reason
  code:
    v: notstarted
  display:
    v: Not Started

title:
  v: All-cause mortality
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: summary-of-findings-entry-for-a-single-outcome
    display:
      v: Summary of findings entry for a single outcome
focus:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236953
  reference:
    v: EvidenceVariable/236953
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313956
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: All-cause mortality
section:
  title:
    v: Outcome
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: outcome-measure
      display:
        v: Outcome Measure
  text:
    status:
      v: generated
    div:
      v: All-cause mortality
  entry:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236953
    reference:
      v: EvidenceVariable/236953
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-313956
    display:
      v: OutcomeDefinition: All-cause mortality
section:
  title:
    v: Sample Size
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: sample-size
      display:
        v: Sample Size
  text:
    status:
      v: generated
    div:
      v: 2 studies, 1282 participants
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236954
    reference:
      v: Evidence/236954
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence
    display:
      v: MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
section:
  title:
    v: Result Without Treatment
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-comparator-alone
      display:
        v: Result with comparator alone
  text:
    status:
      v: generated
    div:
      v: 0.24
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236955
    reference:
      v: Evidence/236955
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Observed
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone
      display:
        v: Result with intervention alone
  text:
    status:
      v: generated
    div:
      v: 0.22
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/293980
    reference:
      v: Evidence/293980
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-intervention-only-evidence
    display:
      v: MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Derived
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone-calculated
      display:
        v: Result with intervention alone (calculated)
    text:
      v: result with intervention with calculated value derived from the control group and effect estimate
  text:
    status:
      v: generated
    div:
      v: 21.8%
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236955
    reference:
      v: Evidence/236955
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236954
    reference:
      v: Evidence/236954
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence

display:
  v: Computable Publishing LLC

v: MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Effect Estimate
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: result-with-intervention-vs-comparator
    display:
      v: Result with intervention vs. comparator
text:
  status:
    v: generated
  div:
    v: Risk Difference -2.3% ( -4% to -0.4%); Odds Ratio 0.88 ( 0.79 to 0.98)
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236954
  reference:
    v: Evidence/236954
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Certainty of Evidence
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: certainty-of-evidence
    display:
      v: Certainty of Evidence
text:
  status:
    v: generated
  div:
    v: Moderate certainty
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236954
  reference:
    v: Evidence/236954
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Assertion
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: assertion
    display:
      v: Assertion
text:
  status:
    v: generated
  div:
    v: SGLT2 inhibitors probably reduce the risk of all cause mortality compared with GLP-1 receptor agonists.
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236954
  reference:
    v: Evidence/236954
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Cardiovascular mortality
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: summary-of-findings-entry-for-a-single-outcome
    display:
      v: Summary of findings entry for a single outcome
focus:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236956
  reference:
    v: EvidenceVariable/236956
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313957
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Cardiovascular mortality
section:
  title:
    v: Outcome
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: outcome-measure
      display:
        v: Outcome Measure
  text:
    status:
      v: generated
    div:
      v: Cardiovascular mortality
  entry:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236956
    reference:
      v: EvidenceVariable/236956
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-313957
    display:
      v: OutcomeDefinition: Cardiovascular mortality
section:
  title:
    v: Sample Size
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: sample-size
      display:
        v: Sample Size
  text:
    status:
      v: generated
    div:
      v: 1 studies, 463 participants
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236957
    reference:
      v: Evidence/236957
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence
    display:
      v: MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
section:
  title:
    v: Result Without Treatment
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-comparator-alone
      display:
        v: Result with comparator alone
  text:
    status:
      v: generated
    div:
      v: 0.16
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236958
    reference:
      v: Evidence/236958
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Observed
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone
      display:
        v: Result with intervention alone
  text:
    status:
      v: generated
    div:
      v: 0.15
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/293981
    reference:
      v: Evidence/293981
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-intervention-only-evidence
    display:
      v: MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Derived
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone-calculated
      display:
        v: Result with intervention alone (calculated)
    text:
      v: result with intervention with calculated value derived from the control group and effect estimate
  text:
    status:
      v: generated
    div:
      v: 15.2%
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236958
    reference:
      v: Evidence/236958
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236957
    reference:
      v: Evidence/236957
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence

display:
  v: Computable Publishing LLC

v: MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Effect Estimate
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: result-with-intervention-vs-comparator
    display:
      v: Result with intervention vs. comparator
text:
  status:
    v: generated
  div:
    v: Risk Difference -0.5% ( -2.2% to 1.2%); Odds Ratio 0.96 ( 0.84 to 1.09)
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236957
  reference:
    v: Evidence/236957
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Certainty of Evidence
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: certainty-of-evidence
    display:
      v: Certainty of Evidence
text:
  status:
    v: generated
  div:
    v: Moderate certainty
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236957
  reference:
    v: Evidence/236957
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Assertion
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: assertion
    display:
      v: Assertion
text:
  status:
    v: generated
  div:
    v: There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236957
  reference:
    v: Evidence/236957
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Nonfatal myocardial infarction
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: summary-of-findings-entry-for-a-single-outcome
    display:
      v: Summary of findings entry for a single outcome
focus:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236959
  reference:
    v: EvidenceVariable/236959
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313958
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Nonfatal myocardial infarction
section:
  title:
    v: Outcome
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: outcome-measure
      display:
        v: Outcome Measure
  text:
    status:
      v: generated
    div:
      v: Nonfatal myocardial infarction
  entry:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236959
    reference:
      v: EvidenceVariable/236959
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-313958
    display:
      v: OutcomeDefinition: Nonfatal myocardial infarction
section:
  title:
    v: Sample Size
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: sample-size
      display:
        v: Sample Size
  text:
    status:
      v: generated
    div:
      v: 1 studies, 463 participants
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236960
    reference:
      v: Evidence/236960
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence
    display:
      v: MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
section:
  title:
    v: Result Without Treatment
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-comparator-alone
      display:
        v: Result with comparator alone
  text:
    status:
      v: generated
    div:
      v: 0.18
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236961
    reference:
      v: Evidence/236961
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Observed
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone
      display:
        v: Result with intervention alone
  text:
    status:
      v: generated
    div:
      v: 0.17
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/293982
    reference:
      v: Evidence/293982
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-intervention-only-evidence
    display:
      v: MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Derived
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone-calculated
      display:
        v: Result with intervention alone (calculated)
    text:
      v: result with intervention with calculated value derived from the control group and effect estimate
  text:
    status:
      v: generated
    div:
      v: 17%
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236961
    reference:
      v: Evidence/236961
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236960
    reference:
      v: Evidence/236960
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence

display:
  v: Computable Publishing LLC

v: MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Effect Estimate
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: result-with-intervention-vs-comparator
    display:
      v: Result with intervention vs. comparator
text:
  status:
    v: generated
  div:
    v: Risk Difference -0.7% ( -2.4% to 1.1%); Odds Ratio 0.95 ( 0.84 to 1.08)
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236960
  reference:
    v: Evidence/236960
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Certainty of Evidence
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: certainty-of-evidence
    display:
      v: Certainty of Evidence
text:
  status:
    v: generated
  div:
    v: Moderate certainty
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236960
  reference:
    v: Evidence/236960
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Assertion
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: assertion
    display:
      v: Assertion
text:
  status:
    v: generated
  div:
    v: There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of nonfatal myocardial infarction.
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236960
  reference:
    v: Evidence/236960
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Nonfatal stroke
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: summary-of-findings-entry-for-a-single-outcome
    display:
      v: Summary of findings entry for a single outcome
focus:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236962
  reference:
    v: EvidenceVariable/236962
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313959
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Nonfatal stroke
section:
  title:
    v: Outcome
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: outcome-measure
      display:
        v: Outcome Measure
  text:
    status:
      v: generated
    div:
      v: Nonfatal stroke
  entry:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236962
    reference:
      v: EvidenceVariable/236962
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-313959
    display:
      v: OutcomeDefinition: Nonfatal stroke
section:
  title:
    v: Sample Size
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: sample-size
      display:
        v: Sample Size
  text:
    status:
      v: generated
    div:
      v: 2 studies, 1282 participants
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236963
    reference:
      v: Evidence/236963
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence
    display:
      v: MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
section:
  title:
    v: Result Without Treatment
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-comparator-alone
      display:
        v: Result with comparator alone
  text:
    status:
      v: generated
    div:
      v: 0.17
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236964
    reference:
      v: Evidence/236964
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Observed
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone
      display:
        v: Result with intervention alone
  text:
    status:
      v: generated
    div:
      v: 0.19
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/293983
    reference:
      v: Evidence/293983
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-intervention-only-evidence
    display:
      v: MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Derived
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone-calculated
      display:
        v: Result with intervention alone (calculated)
    text:
      v: result with intervention with calculated value derived from the control group and effect estimate
  text:
    status:
      v: generated
    div:
      v: 19.2%
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236964
    reference:
      v: Evidence/236964
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236963
    reference:
      v: Evidence/236963
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence

display:
  v: Computable Publishing LLC

v: MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Effect Estimate
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: result-with-intervention-vs-comparator
    display:
      v: Result with intervention vs. comparator
text:
  status:
    v: generated
  div:
    v: Risk Difference 2.7% ( 0.4% to 5.3%); Odds Ratio 1.2 ( 1.03 to 1.41)
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236963
  reference:
    v: Evidence/236963
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Certainty of Evidence
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: certainty-of-evidence
    display:
      v: Certainty of Evidence
text:
  status:
    v: generated
  div:
    v: Moderate certainty
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236963
  reference:
    v: Evidence/236963
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Assertion
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: assertion
    display:
      v: Assertion
text:
  status:
    v: generated
  div:
    v: SGLT2 inhibitors probably increase the risk of nonfatal stroke compared with GLP-1 receptor agonists.
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236963
  reference:
    v: Evidence/236963
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: End-stage kidney disease
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: summary-of-findings-entry-for-a-single-outcome
    display:
      v: Summary of findings entry for a single outcome
focus:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236965
  reference:
    v: EvidenceVariable/236965
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313960
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: End-stage kidney disease
section:
  title:
    v: Outcome
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: outcome-measure
      display:
        v: Outcome Measure
  text:
    status:
      v: generated
    div:
      v: End-stage kidney disease
  entry:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236965
    reference:
      v: EvidenceVariable/236965
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-313960
    display:
      v: OutcomeDefinition: End-stage kidney disease
section:
  title:
    v: Sample Size
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: sample-size
      display:
        v: Sample Size
  text:
    status:
      v: generated
    div:
      v: 1 studies, 463 participants
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236966
    reference:
      v: Evidence/236966
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence
    display:
      v: MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
section:
  title:
    v: Result Without Treatment
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-comparator-alone
      display:
        v: Result with comparator alone
  text:
    status:
      v: generated
    div:
      v: 0.12
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236967
    reference:
      v: Evidence/236967
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Observed
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone
      display:
        v: Result with intervention alone
  text:
    status:
      v: generated
    div:
      v: 0.11
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/293984
    reference:
      v: Evidence/293984
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-intervention-only-evidence
    display:
      v: MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Derived
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone-calculated
      display:
        v: Result with intervention alone (calculated)
    text:
      v: result with intervention with calculated value derived from the control group and effect estimate
  text:
    status:
      v: generated
    div:
      v: 10.9%
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236967
    reference:
      v: Evidence/236967
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236966
    reference:
      v: Evidence/236966
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence

display:
  v: Computable Publishing LLC

v: MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Effect Estimate
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: result-with-intervention-vs-comparator
    display:
      v: Result with intervention vs. comparator
text:
  status:
    v: generated
  div:
    v: Risk Difference -1% ( -3.4% to 2%); Odds Ratio 0.91 ( 0.69 to 1.2)
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236966
  reference:
    v: Evidence/236966
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Certainty of Evidence
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: certainty-of-evidence
    display:
      v: Certainty of Evidence
text:
  status:
    v: generated
  div:
    v: Moderate certainty
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236966
  reference:
    v: Evidence/236966
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Assertion
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: assertion
    display:
      v: Assertion
text:
  status:
    v: generated
  div:
    v: There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236966
  reference:
    v: Evidence/236966
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Heart failure
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: summary-of-findings-entry-for-a-single-outcome
    display:
      v: Summary of findings entry for a single outcome
focus:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236968
  reference:
    v: EvidenceVariable/236968
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313961
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Heart failure
section:
  title:
    v: Outcome
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: outcome-measure
      display:
        v: Outcome Measure
  text:
    status:
      v: generated
    div:
      v: Heart failure
  entry:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236968
    reference:
      v: EvidenceVariable/236968
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-313961
    display:
      v: OutcomeDefinition: Heart failure
section:
  title:
    v: Sample Size
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: sample-size
      display:
        v: Sample Size
  text:
    status:
      v: empty
    div:
      v: [No sample size data found.]
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236969
    reference:
      v: Evidence/236969
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence
    display:
      v: MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
section:
  title:
    v: Result Without Treatment
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-comparator-alone
      display:
        v: Result with comparator alone
  text:
    status:
      v: generated
    div:
      v: 0.22
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236970
    reference:
      v: Evidence/236970
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Observed
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone
      display:
        v: Result with intervention alone
  text:
    status:
      v: generated
    div:
      v: 0.18
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/293985
    reference:
      v: Evidence/293985
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-intervention-only-evidence
    display:
      v: MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Derived
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone-calculated
      display:
        v: Result with intervention alone (calculated)
    text:
      v: result with intervention with calculated value derived from the control group and effect estimate
  text:
    status:
      v: generated
    div:
      v: 17.6%
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236970
    reference:
      v: Evidence/236970
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236969
    reference:
      v: Evidence/236969
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence

display:
  v: Computable Publishing LLC

v: MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Effect Estimate
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: result-with-intervention-vs-comparator
    display:
      v: Result with intervention vs. comparator
text:
  status:
    v: generated
  div:
    v: Risk Difference -4.8% ( -6.6% to -2.7%); Odds Ratio 0.74 ( 0.65 to 0.85)
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236969
  reference:
    v: Evidence/236969
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Certainty of Evidence
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: certainty-of-evidence
    display:
      v: Certainty of Evidence
text:
  status:
    v: generated
  div:
    v: High certainty
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236969
  reference:
    v: Evidence/236969
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Assertion
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: assertion
    display:
      v: Assertion
text:
  status:
    v: generated
  div:
    v: SGLT2 inhibitors reduce the risk of heart failure compared with GLP-1 receptor agonists.
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236969
  reference:
    v: Evidence/236969
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Diabetic ketoacidosis
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: summary-of-findings-entry-for-a-single-outcome
    display:
      v: Summary of findings entry for a single outcome
focus:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236971
  reference:
    v: EvidenceVariable/236971
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313962
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Diabetic ketoacidosis
section:
  title:
    v: Outcome
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: outcome-measure
      display:
        v: Outcome Measure
  text:
    status:
      v: generated
    div:
      v: Diabetic ketoacidosis
  entry:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236971
    reference:
      v: EvidenceVariable/236971
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-313962
    display:
      v: OutcomeDefinition: Diabetic ketoacidosis
section:
  title:
    v: Sample Size
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: sample-size
      display:
        v: Sample Size
  text:
    status:
      v: generated
    div:
      v: 1 studies, 463 participants
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236972
    reference:
      v: Evidence/236972
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence
    display:
      v: MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
section:
  title:
    v: Result Without Treatment
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-comparator-alone
      display:
        v: Result with comparator alone
  text:
    status:
      v: generated
    div:
      v: 0
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236973
    reference:
      v: Evidence/236973
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Observed
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone
      display:
        v: Result with intervention alone
  text:
    status:
      v: generated
    div:
      v: 0
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/293986
    reference:
      v: Evidence/293986
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-intervention-only-evidence
    display:
      v: MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Derived
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone-calculated
      display:
        v: Result with intervention alone (calculated)
    text:
      v: result with intervention with calculated value derived from the control group and effect estimate
  text:
    status:
      v: generated
    div:
      v: 0.2%
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236973
    reference:
      v: Evidence/236973
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236972
    reference:
      v: Evidence/236972
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence

display:
  v: Computable Publishing LLC

v: MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Effect Estimate
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: result-with-intervention-vs-comparator
    display:
      v: Result with intervention vs. comparator
text:
  status:
    v: generated
  div:
    v: Risk Difference 0.1% ( 0% to 0.3%); Odds Ratio 1.71 ( 0.79 to 3.69)
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236972
  reference:
    v: Evidence/236972
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Certainty of Evidence
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: certainty-of-evidence
    display:
      v: Certainty of Evidence
text:
  status:
    v: generated
  div:
    v: High certainty
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236972
  reference:
    v: Evidence/236972
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Assertion
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: assertion
    display:
      v: Assertion
text:
  status:
    v: generated
  div:
    v: There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of diabetic ketoacidosis.
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236972
  reference:
    v: Evidence/236972
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Serious hyperglycaemia
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: summary-of-findings-entry-for-a-single-outcome
    display:
      v: Summary of findings entry for a single outcome
focus:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236974
  reference:
    v: EvidenceVariable/236974
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313963
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Serious hyperglycaemia
section:
  title:
    v: Outcome
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: outcome-measure
      display:
        v: Outcome Measure
  text:
    status:
      v: generated
    div:
      v: Serious hyperglycaemia
  entry:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236974
    reference:
      v: EvidenceVariable/236974
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-313963
    display:
      v: OutcomeDefinition: Serious hyperglycaemia
section:
  title:
    v: Sample Size
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: sample-size
      display:
        v: Sample Size
  text:
    status:
      v: generated
    div:
      v: 1 studies, 463 participants
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236975
    reference:
      v: Evidence/236975
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence
    display:
      v: MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
section:
  title:
    v: Result Without Treatment
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-comparator-alone
      display:
        v: Result with comparator alone
  text:
    status:
      v: generated
    div:
      v: 0.01
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236976
    reference:
      v: Evidence/236976
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Observed
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone
      display:
        v: Result with intervention alone
  text:
    status:
      v: generated
    div:
      v: 0.01
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/293987
    reference:
      v: Evidence/293987
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-intervention-only-evidence
    display:
      v: MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Derived
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone-calculated
      display:
        v: Result with intervention alone (calculated)
    text:
      v: result with intervention with calculated value derived from the control group and effect estimate
  text:
    status:
      v: generated
    div:
      v: 1.5%
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236976
    reference:
      v: Evidence/236976
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236975
    reference:
      v: Evidence/236975
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence

display:
  v: Computable Publishing LLC

v: MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Effect Estimate
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: result-with-intervention-vs-comparator
    display:
      v: Result with intervention vs. comparator
text:
  status:
    v: generated
  div:
    v: Risk Difference 0.5% ( -0.2% to 1.9%); Odds Ratio 1.48 ( 0.75 to 2.93)
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236975
  reference:
    v: Evidence/236975
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Certainty of Evidence
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: certainty-of-evidence
    display:
      v: Certainty of Evidence
text:
  status:
    v: generated
  div:
    v: High certainty
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236975
  reference:
    v: Evidence/236975
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Assertion
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: assertion
    display:
      v: Assertion
text:
  status:
    v: generated
  div:
    v: There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of serious hyperglycaemia.
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236975
  reference:
    v: Evidence/236975
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Genital infection
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: summary-of-findings-entry-for-a-single-outcome
    display:
      v: Summary of findings entry for a single outcome
focus:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236977
  reference:
    v: EvidenceVariable/236977
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313964
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Genital infection
section:
  title:
    v: Outcome
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: outcome-measure
      display:
        v: Outcome Measure
  text:
    status:
      v: generated
    div:
      v: Genital infection
  entry:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236977
    reference:
      v: EvidenceVariable/236977
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-313964
    display:
      v: OutcomeDefinition: Genital infection
section:
  title:
    v: Sample Size
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: sample-size
      display:
        v: Sample Size
  text:
    status:
      v: generated
    div:
      v: 2 studies, 1282 participants
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236978
    reference:
      v: Evidence/236978
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence
    display:
      v: MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
section:
  title:
    v: Result Without Treatment
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-comparator-alone
      display:
        v: Result with comparator alone
  text:
    status:
      v: generated
    div:
      v: 0.05
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236979
    reference:
      v: Evidence/236979
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Observed
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone
      display:
        v: Result with intervention alone
  text:
    status:
      v: generated
    div:
      v: 0.21
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/293988
    reference:
      v: Evidence/293988
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-intervention-only-evidence
    display:
      v: MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Derived
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone-calculated
      display:
        v: Result with intervention alone (calculated)
    text:
      v: result with intervention with calculated value derived from the control group and effect estimate
  text:
    status:
      v: generated
    div:
      v: 20.8%
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236979
    reference:
      v: Evidence/236979
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236978
    reference:
      v: Evidence/236978
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence

display:
  v: Computable Publishing LLC

v: MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Effect Estimate
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: result-with-intervention-vs-comparator
    display:
      v: Result with intervention vs. comparator
text:
  status:
    v: generated
  div:
    v: Risk Difference 15.8% ( 6.4% to 29.9%); Odds Ratio 5 ( 2.45 to 10.2)
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236978
  reference:
    v: Evidence/236978
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Certainty of Evidence
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: certainty-of-evidence
    display:
      v: Certainty of Evidence
text:
  status:
    v: generated
  div:
    v: High certainty
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236978
  reference:
    v: Evidence/236978
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Assertion
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: assertion
    display:
      v: Assertion
text:
  status:
    v: generated
  div:
    v: SGLT2 inhibitors increase the risk of genital infection compared with GLP-1 receptor agonists.
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236978
  reference:
    v: Evidence/236978
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Severe gastrointestinal events
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: summary-of-findings-entry-for-a-single-outcome
    display:
      v: Summary of findings entry for a single outcome
focus:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236980
  reference:
    v: EvidenceVariable/236980
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313965
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Severe gastrointestinal events
section:
  title:
    v: Outcome
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: outcome-measure
      display:
        v: Outcome Measure
  text:
    status:
      v: generated
    div:
      v: Severe gastrointestinal events
  entry:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236980
    reference:
      v: EvidenceVariable/236980
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-313965
    display:
      v: OutcomeDefinition: Severe gastrointestinal events
section:
  title:
    v: Sample Size
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: sample-size
      display:
        v: Sample Size
  text:
    status:
      v: generated
    div:
      v: 7 studies, 24638 participants
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236981
    reference:
      v: Evidence/236981
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence
    display:
      v: MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
section:
  title:
    v: Result Without Treatment
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-comparator-alone
      display:
        v: Result with comparator alone
  text:
    status:
      v: generated
    div:
      v: 0.04
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236982
    reference:
      v: Evidence/236982
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Observed
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone
      display:
        v: Result with intervention alone
  text:
    status:
      v: generated
    div:
      v: 0.1
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/293989
    reference:
      v: Evidence/293989
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-intervention-only-evidence
    display:
      v: MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Derived
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone-calculated
      display:
        v: Result with intervention alone (calculated)
    text:
      v: result with intervention with calculated value derived from the control group and effect estimate
  text:
    status:
      v: generated
    div:
      v: 10.2%
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236982
    reference:
      v: Evidence/236982
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236981
    reference:
      v: Evidence/236981
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence

display:
  v: Computable Publishing LLC

v: MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Effect Estimate
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: result-with-intervention-vs-comparator
    display:
      v: Result with intervention vs. comparator
text:
  status:
    v: generated
  div:
    v: Risk Difference 5.8% ( 0.9% to 14.2%); Odds Ratio 2.46 ( 1.22 to 4.97)
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236981
  reference:
    v: Evidence/236981
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Certainty of Evidence
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: certainty-of-evidence
    display:
      v: Certainty of Evidence
text:
  status:
    v: generated
  div:
    v: Very low certainty
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236981
  reference:
    v: Evidence/236981
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Assertion
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: assertion
    display:
      v: Assertion
text:
  status:
    v: generated
  div:
    v: GLP-1 receptor agonists may increase the risk of severe gastrointestinal events compared with SGLT2 inhibitors.
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236981
  reference:
    v: Evidence/236981
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Health-related quality of life
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: summary-of-findings-entry-for-a-single-outcome
    display:
      v: Summary of findings entry for a single outcome
focus:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236983
  reference:
    v: EvidenceVariable/236983
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-109587
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Health-related quality of life
section:
  title:
    v: Outcome
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: outcome-measure
      display:
        v: Outcome Measure
  text:
    status:
      v: generated
    div:
      v: Health-related quality of life
  entry:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236983
    reference:
      v: EvidenceVariable/236983
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-109587
    display:
      v: OutcomeDefinition: Health-related quality of life
section:
  title:
    v: Sample Size
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: sample-size
      display:
        v: Sample Size
  text:
    status:
      v: empty
    div:
      v: [No sample size data found.]
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236984
    reference:
      v: Evidence/236984
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence
    display:
      v: MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
section:
  title:
    v: Result Without Treatment
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-comparator-alone
      display:
        v: Result with comparator alone
  text:
    status:
      v: empty
    div:
      v: [Not a proportion.]
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236985
    reference:
      v: Evidence/236985
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Observed
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone
      display:
        v: Result with intervention alone
  text:
    status:
      v: empty
    div:
      v: [Not a proportion.]
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/293990
    reference:
      v: Evidence/293990
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-continuous-outcome-109587-intervention-only-evidence
    display:
      v: MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Derived
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone-calculated
      display:
        v: Result with intervention alone (calculated)
    text:
      v: result with intervention with calculated value derived from the control group and effect estimate
  text:
    status:
      v: generated
    div:
      v: [Not a proportion.]
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236985
    reference:
      v: Evidence/236985
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236984
    reference:
      v: Evidence/236984
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence

display:
  v: Computable Publishing LLC

v: MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Effect Estimate
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: result-with-intervention-vs-comparator
    display:
      v: Result with intervention vs. comparator
text:
  status:
    v: generated
  div:
    v: Standardized Mean Difference 0.01 ( -0.19 to 0.2)
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236984
  reference:
    v: Evidence/236984
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Certainty of Evidence
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: certainty-of-evidence
    display:
      v: Certainty of Evidence
text:
  status:
    v: generated
  div:
    v: Low certainty
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236984
  reference:
    v: Evidence/236984
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Assertion
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: assertion
    display:
      v: Assertion
text:
  status:
    v: generated
  div:
    v: There may be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on health-related quality of life.
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236984
  reference:
    v: Evidence/236984
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Body weight
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: summary-of-findings-entry-for-a-single-outcome
    display:
      v: Summary of findings entry for a single outcome
focus:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236986
  reference:
    v: EvidenceVariable/236986
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-109588
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Body weight
section:
  title:
    v: Outcome
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: outcome-measure
      display:
        v: Outcome Measure
  text:
    status:
      v: generated
    div:
      v: Body weight
  entry:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236986
    reference:
      v: EvidenceVariable/236986
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-109588
    display:
      v: OutcomeDefinition: Body weight
section:
  title:
    v: Sample Size
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: sample-size
      display:
        v: Sample Size
  text:
    status:
      v: generated
    div:
      v: 2 studies, 1139 participants
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236987
    reference:
      v: Evidence/236987
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence
    display:
      v: MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
section:
  title:
    v: Result Without Treatment
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-comparator-alone
      display:
        v: Result with comparator alone
  text:
    status:
      v: empty
    div:
      v: [Not a proportion.]
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236988
    reference:
      v: Evidence/236988
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Observed
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone
      display:
        v: Result with intervention alone
  text:
    status:
      v: empty
    div:
      v: [Not a proportion.]
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/293991
    reference:
      v: Evidence/293991
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-continuous-outcome-109588-intervention-only-evidence
    display:
      v: MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
section:
  title:
    v: Result With Treatment--Derived
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: result-with-intervention-alone-calculated
      display:
        v: Result with intervention alone (calculated)
    text:
      v: result with intervention with calculated value derived from the control group and effect estimate
  text:
    status:
      v: generated
    div:
      v: [Not a proportion.]
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236988
    reference:
      v: Evidence/236988
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparator-only-evidence
    display:
      v: MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
  entry:
    l: http://hl7.org/fhir/uv/ebm/Evidence/236987
    reference:
      v: Evidence/236987
    type:
      v: Evidence
      l: Evidence
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence

display:
  v: Computable Publishing LLC

v: MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Effect Estimate
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: result-with-intervention-vs-comparator
    display:
      v: Result with intervention vs. comparator
text:
  status:
    v: generated
  div:
    v: Mean Difference -0.47 Kg ( -0.09 Kg to -0.85 Kg)
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236987
  reference:
    v: Evidence/236987
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Certainty of Evidence
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: certainty-of-evidence
    display:
      v: Certainty of Evidence
text:
  status:
    v: generated
  div:
    v: Moderate certainty
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236987
  reference:
    v: Evidence/236987
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Assertion
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: assertion
    display:
      v: Assertion
text:
  status:
    v: generated
  div:
    v: SGLT2 inhibitors probably reduce body weight compared with GLP-1 receptor agonists.
entry:
  l: http://hl7.org/fhir/uv/ebm/Evidence/236987
  reference:
    v: Evidence/236987
  type:
    v: Evidence
    l: Evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

title:
  v: Groups
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: groups
    display:
      v: Groups
section:
  title:
    v: Total Group
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: population
      display:
        v: Population
  text:
    status:
      v: empty
    div:
      v: [No data.]
  empty reason:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/list-empty-reason
        l: list-empty-reason
      code:
        v: notstarted
      display:
        v: Not Started
section:
  title:
    v: Intervention Group
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: intervention-group
      display:
        v: Intervention Group
  text:
    status:
      v: empty
    div:
      v: [No data.]
  empty reason:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/list-empty-reason
        l: list-empty-reason
      code:
        v: notstarted
      display:
        v: Not Started
section:
  title:
    v: Comparator Group
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: comparator-group
      display:
        v: Comparator Group
  text:
    status:
      v: empty
    div:
      v: [No data.]
  empty reason:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/list-empty-reason
        l: list-empty-reason
      code:
        v: notstarted
      display:
        v: Not Started
section:
  title:
    v: Group Assignment
  code:
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: GroupAssignment
      display:
        v: GroupAssignment
  text:
    status:
      v: empty
    div:
      v: [No data.]
  empty reason:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/list-empty-reason
        l: list-empty-reason
      code:
        v: notstarted
      display:
        v: Not Started

title:
  v: Variables (Measures)
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: variables
    display:
      v: Variables
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236953
  reference:
    v: EvidenceVariable/236953
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313956
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: All-cause mortality
entry:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236956
  reference:
    v: EvidenceVariable/236956
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313957
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Cardiovascular mortality
entry:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236959
  reference:
    v: EvidenceVariable/236959
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313958
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Nonfatal myocardial infarction
entry:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236962
  reference:
    v: EvidenceVariable/236962
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313959
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Nonfatal stroke
entry:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236965
  reference:
    v: EvidenceVariable/236965
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313960
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: End-stage kidney disease
entry:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236968
  reference:
    v: EvidenceVariable/236968
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313961
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Heart failure
entry:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236971
  reference:
    v: EvidenceVariable/236971
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313962
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Diabetic ketoacidosis
entry:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236974
  reference:
    v: EvidenceVariable/236974
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313963
    assigner:
      display:
        v: Computable Publishing LLC
  display:
    v: OutcomeDefinition: Serious hyperglycaemia
entry:
  l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236977
  reference:
    v: EvidenceVariable/236977
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: MAGIC-5288-j1Wqrn-313964
    assigner:
      display:
        v: Computable Publishing LLC

v: OutcomeDefinition: Genital infection

l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236980
reference:
  v: EvidenceVariable/236980
type:
  v: EvidenceVariable
  l: EvidenceVariable
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: MAGIC-5288-j1Wqrn-313965
  assigner:
    display:
      v: Computable Publishing LLC
display:
  v: OutcomeDefinition: Severe gastrointestinal events

l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236983
reference:
  v: EvidenceVariable/236983
type:
  v: EvidenceVariable
  l: EvidenceVariable
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: MAGIC-5288-j1Wqrn-109587
  assigner:
    display:
      v: Computable Publishing LLC
display:
  v: OutcomeDefinition: Health-related quality of life

l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236986
reference:
  v: EvidenceVariable/236986
type:
  v: EvidenceVariable
  l: EvidenceVariable
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: MAGIC-5288-j1Wqrn-109588
  assigner:
    display:
      v: Computable Publishing LLC
display:
  v: OutcomeDefinition: Body weight